Clinical Trial Update: Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) [Phase 3]

View source ↗

Summary

Phase 3 trial update showing the efficacy, safety and long-term prognosis of imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis | Conditions: Chronic Myelogenous Leukemia in Chronic Phase | Phase 3 | Status: COMPLETED